Illumina (company)

Illumina (company). Illumina is a global leader in DNA sequencing and array-based technologies, providing tools and services that enable advancements in life sciences, oncology, and reproductive health. Founded in 1998, the company's platforms are instrumental in genomic research, clinical diagnostics, and agricultural biotechnology. Its technologies have been pivotal in large-scale projects like the All of Us Research Program and have driven down the cost of sequencing a human genome dramatically since the completion of the Human Genome Project.

History

The company was co-founded in 1998 by scientists including David R. Walt, a core inventor of the technology, alongside Larry Bock, John Stuelpnagel, Anthony Czarnik, and Mark Chee. Its early work focused on BeadArray technology using fiber-optic bundles. A significant early partnership was formed with Affymetrix, a major player in DNA microarrays. Illumina went public on the NASDAQ in 2000. A transformative acquisition came in 2007 with the purchase of Solexa, which provided the sequencing by synthesis (SBS) chemistry that became the cornerstone of its dominant Next-generation sequencing (NGS) platforms. Further strategic acquisitions included Verinata Health in 2013, strengthening its position in non-invasive prenatal testing (NIPT), and Pacific Biosciences (PacBio) in 2019, although this deal was later abandoned after intervention by the Federal Trade Commission (FTC) and the European Commission.

Products and technologies

Illumina's core product lines are built around its proprietary Sequencing by synthesis (SBS) chemistry. Its flagship NextSeq and NovaSeq series of instruments are workhorses for high-throughput sequencing in large genomics centers and biopharmaceutical companies. The smaller MiSeq and iSeq systems cater to lower-throughput clinical and research labs. Beyond instruments, the company produces a vast array of sequencing consumables, such as flow cells and sequencing reagents. Its Infinium assay technology powers genotyping and methylation analysis on BeadChip microarrays. The company also offers the TruSight portfolio for hereditary disease testing and partners with Roche on companion diagnostics. Its DRAGEN Bio-IT Platform provides secondary analysis via field-programmable gate array (FPGA) hardware and cloud computing.

Business operations

Illumina is headquartered in San Diego, California, with major manufacturing and operational sites in Hayward, California, and Singapore. It operates globally through a direct sales force and a network of distributors, serving customers including academic institutions, government laboratories, pharmaceutical companies, and clinical sequencing labs. A significant portion of its revenue comes from the recurring sale of consumables for its installed base of sequencers. The company's commercial strategy has included the establishment of the Illumina Accelerator to fund startup companies in the genomics space. Its operations were significantly impacted by the attempted acquisition of GRAIL, a company developing liquid biopsy tests for early cancer detection.

Corporate affairs

Leadership has included long-time CEO Jay Flatley, followed by Francis deSouza, and later Jacob Thaysen. The company's governance and strategic direction have been influenced by activist investors, notably Carl Icahn, who secured board seats in 2023. Illumina maintains numerous collaborations, such as with the Broad Institute and UK Biobank, and its technology was critical during the COVID-19 pandemic for tracking SARS-CoV-2 variants. The company is a regular participant in major industry conferences like the JP Morgan Healthcare Conference and the American Society of Human Genetics (ASHG) annual meeting. Its corporate social responsibility initiatives include the Illumina Foundation.

Controversies and legal issues

Illumina has faced significant regulatory and legal challenges, most prominently surrounding its $7.1 billion acquisition of GRAIL in 2021. The company completed the deal without awaiting antitrust clearances from the European Commission and the Federal Trade Commission (FTC), both of which later moved to block it, arguing it would stifle innovation in the cancer screening market. In 2023, the FTC issued a divestiture order, and the European Commission imposed a record fine. Illumina is appealing these decisions. Separately, the company has been involved in patent litigation with competitors like Qiagen and BGI Group, including disputes over DNA sequencing patents originally filed by Solexa. These legal battles have created uncertainty for the company and its stakeholders.

Category:Biotechnology companies of the United States Category:Companies listed on NASDAQ Category:San Diego